A Multi-center, randomized, double-blinded, double-dummy, parallel-controlled clinical trial to determine the efficacy and safety of calcipotriol ointment, betamethasone dipropionate ointment and calcipotriol/betamethasone ointment in patients with mild psoriasis vulgaris

Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12003543

Enrollment

Unknown

Registered

2012-12-18

Start date

2011-08-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Psoriasis Vulgaris

Interventions

Calcipotriol Ointment Group:Topical use Calcipotriol Ointment,twice per day

Betamethasone Dipropionate Cream Group:Topical use the placebo in the morning and betamethasone dipropionate cream in the evening

Calcipotriol/Betamethasone Ointment Group:Topical use the placebo in the morning and calcipotriol/betamethasone in the evening

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Males and females aged between 18 and 75 years; (2) Mild psoriasis vulgaris defined by the following criteria: Body surface area (BSA)<10% at screening and baseline and PASI<7 at screening and baseline; (3) Provide written informed consent and Willing and able to comply with all aspects of the protocol.

Exclusion criteria

Exclusion criteria: (1) Other types of psoriasis than mild psoriasis vulgaris eg, guttate, pustular, erythodermic, etc; (2) Psoriasis vulgaris involving only on face, scalp, or flexures; (3) Pregnant or lactating females; (4) Patients with hypercalcemia, renal dysfunction and renal calculus; (5) Any topical treatment for psoriasis within 2 weeks prior to randomisation; (6) Systemic treatment for psoriasis within 4 weeks prior to randomisation; (7) patients who allergy for any ingredient of the drug to be studied; (8) with serious systemic disease; (9) Any other situations not suitable for this study determined by the investigators.

Design outcomes

Primary

Measure	Time frame
PASI75;	—

Secondary

Measure	Time frame
PASI 90;PASI 50;	—

Countries

China

Contacts

Public ContactBaoxi Wang

Institute of Dermatology, Chinese Academy of Medical Sciences

wangbx@ncstdlc.org+86 025-85478071

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026